Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BLSM

BlossomHill Therapeutics Inc

16.38

Aug 21 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Index	-
Market Cap	501.94M
Enterprise Value	665.79M
Income	-
Sales	-
Book/sh	-4.96
Cash/sh	3.79
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	63
IPO	Aug 07, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	4.33
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.37
Current Ratio	7.37
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	35.36%
Insider Trans	16.99%
Inst Own	17.70%
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.16%
SMA50	1.16%
SMA200	1.16%
Trades

Shs Outstand	30.64M
Shs Float	21.44M
Short Float	-
Short Ratio	-
Short Interest	-
52W High	17.25 -5.04%
52W Low	15.25 7.41%
Volatility	4.25% -
ATR (14)	0.78
RSI (14)	-
Beta	-
Rel Volume	0.00
Avg Volume	426.68K
Volume	0

Perf Week	1.24%
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	4.00%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	16.38
Price	16.38
Change %	0.00%

Aug-18-26 07:00AM

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

(GlobeNewswire)

Blossomhill Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded on June 22, 2020 and is headquartered in San Diego, CA.

Ph.D.Dr. Li Yishan M.B.A.

Scientific FounderDr. Jingrong Jean Cui Ph.D.

CFO & Executive VPMr. Jason A. Keyes M.B.A.

Chief Medical Officer & Executive VPDr. Geoff Oxnard M.D.

M.B.A.Dr. Vincent Liptak J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GORDON CARL L	Director	Aug 10 '26	Buy	16.00	625,000	10,000,000	2,714,279	Aug 12 04:46 PM
ORBIMED ADVISORS LLC	Director	Aug 10 '26	Buy	16.00	625,000	10,000,000	2,714,279	Aug 12 04:43 PM
Schmid John P.	Director	Aug 10 '26	Buy	16.00	6,000	96,000	6,000	Aug 10 06:35 PM
Chen Bihua	Director	Aug 10 '26	Buy	16.00	312,500	5,000,000	3,614,034	Aug 10 06:32 PM
Keyes Jason A	Chief Financial Officer	Aug 10 '26	Buy	16.00	700	11,200	700	Aug 10 06:27 PM
Liptak Vincent Paul	General Counsel	Aug 07 '26	Buy	15.80	2,500	39,500	109,212	Aug 10 06:26 PM
Liptak Vincent Paul	General Counsel	Aug 10 '26	Buy	16.00	2,200	35,200	111,412	Aug 10 06:26 PM

SCTX Scribe Therapeutics Inc daily Stock Chart

Peers: IPSC PRME CMPX PRLD BEAM NTLA LXEO RCKT CRSP ABEO

| Held by: ARKG VTI VXF HLTH TNXT VTWO

Index	-
Market Cap	643.84M
Enterprise Value	760.80M
Income	-
Sales	-
Book/sh	-9.03
Cash/sh	2.64
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	98
IPO	Jul 24, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	12.95
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.66
Current Ratio	0.66
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-2.97
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Jun 03
EPS/Sales Surpr.	- -

Insider Own	42.13%
Insider Trans	147.02%
Inst Own	25.93%
Inst Trans	13.15%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	44.57%
SMA50	45.14%
SMA200	45.14%
Trades

Shs Outstand	17.58M
Shs Float	10.92M
Short Float	2.41%
Short Ratio	1.02
Short Interest	0.26M
52W High	39.60 -13.81%
52W Low	17.31 97.23%
Volatility	20.24% -
ATR (14)	3.65
RSI (14)	72.76
Beta	-
Rel Volume	0.00
Avg Volume	256.97K
Volume	0

Perf Week	64.64%
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	36.52%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	49.00
Prev Close	34.13
Price	34.13
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-18-26	Initiated	Wells Fargo	Overweight	$60
Aug-18-26	Initiated	Leerink Partners	Outperform	$37
Aug-18-26	Initiated	Guggenheim	Buy	$50

Aug-18-26 09:37AM	Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls (The Fly) +27.94%
Jul-27-26 04:08PM	Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com) -12.38%
04:05PM	Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement (GlobeNewswire)
Jul-24-26 02:45PM	Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO (GuruFocus.com)

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.

Co-FounderDr. Benjamin L. Oakes Ph.D.

CFO & TreasurerMr. David L. Parrot M.B.A.

Chief Business OfficerDr. Svetlana Lucas Ph.D.

Co-Founder & Scientific AdvisorDr. Jennifer A. Doudna Ph.D.

Co-Founder & VP of External InnovationMr. Brett T. Staahl Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AH Bio Fund II, L.P.	10% Owner	Jul 27 '26	Buy	15.00	333,333	4,999,995	2,385,075	Jul 29 07:09 PM
GORDON CARL L	Director	Jul 27 '26	Buy	15.00	1,000,000	15,000,000	1,348,825	Jul 29 06:50 PM
ORBIMED ADVISORS LLC	Director	Jul 27 '26	Buy	15.00	1,000,000	15,000,000	1,348,825	Jul 29 06:47 PM
Aghazadeh Behzad	Director	Jul 24 '26	Buy	15.15	2,383,333	36,115,495	3,080,983	Jul 28 09:30 PM
Aghazadeh Behzad	Director	Jul 28 '26	Buy	18.25	7,905	144,266	3,088,888	Jul 28 09:30 PM
Lucas Svetlana	Chief Business Officer	Jul 23 '26	Buy	15.00	3,000	45,000	3,000	Jul 27 09:42 PM
Parrot David	Chief Financial Officer	Jul 23 '26	Buy	15.00	2,666	39,990	1,333	Jul 27 09:20 PM

CMPX Compass Therapeutics Inc daily Stock Chart

Peers: ARVN BBOT CGEM ALLO RIGL GERN CTMX JANX KURA XNCR

| Held by: XBI IWM VTI FESM VXF IWN VTWO IWC LABU ITOT

Index	RUT
Market Cap	432.21M
Enterprise Value	261.96M
Income	-73.45M
Sales	0.00M
Book/sh	0.92
Cash/sh	1.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	39
IPO	Apr 05, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.60
P/C	2.40
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.22
Current Ratio	11.22
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-0.40
EPS next Y	-0.55
EPS next Q	-0.13
EPS this Y	-19.21%
EPS next Y	-10.42%
EPS next 5Y	19.58%
EPS past 3/5Y	-4.18% 5.72%
Sales past 3/5Y	- -
EPS Y/Y TTM	10.44%
Sales Y/Y TTM	-100.00%
EPS Q/Q	6.33%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-17.43% 100.00%

Insider Own	24.17%
Insider Trans	0.00%
Inst Own	73.27%
Inst Trans	-0.37%
ROA	-47.87%
ROE	-56.66%
ROIC	-42.20%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	10.69%
SMA50	11.77%
SMA200	-41.02%
Trades

Shs Outstand	180.09M
Shs Float	136.57M
Short Float	29.20%
Short Ratio	11.65
Short Interest	39.87M
52W High	6.88 -65.12%
52W Low	1.61 49.07%
Volatility	6.53% 6.17%
ATR (14)	0.13
RSI (14)	60.31
Beta	0.84
Rel Volume	0.01
Avg Volume	3.42M
Volume	937

Perf Week	3.90%
Perf Month	15.94%
Perf Quarter	15.94%
Perf Half Y	-59.25%
Perf YTD	-55.31%
Perf Year	-20.53%
Perf 3Y	-0.83%
Perf 5Y	-38.46%
Perf 10Y	-
Recom	1.13
Target Price	8.92
Prev Close	2.40
Price	2.40
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-26	Resumed	Ladenburg Thalmann	Buy	$5
Apr-28-26	Downgrade	Raymond James	Outperform → Mkt Perform
Feb-13-26	Initiated	Craig Hallum	Buy	$15
Jan-05-26	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Citizens JMP	Mkt Outperform	$10
Dec-03-25	Initiated	Cantor Fitzgerald	Overweight
Dec-03-25	Initiated	Canaccord Genuity	Buy	$10
Jul-01-25	Resumed	Raymond James	Outperform	$9
Apr-02-25	Upgrade	Leerink Partners	Market Perform → Outperform	$6
Feb-24-25	Initiated	Guggenheim	Buy	$12
Feb-19-25	Initiated	Piper Sandler	Overweight	$12
Dec-23-24	Initiated	D. Boral Capital	Buy	$32
Nov-15-24	Downgrade	Leerink Partners	Outperform → Market Perform	$5 → $4
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$5
Jan-31-23	Initiated	Jefferies	Buy	$8
Jan-27-23	Initiated	Stifel	Buy	$9
May-23-22	Resumed	H.C. Wainwright	Buy	$12
Mar-15-22	Initiated	Ladenburg Thalmann	Buy	$7
Jan-19-22	Initiated	B. Riley Securities	Buy	$10
Dec-22-21	Initiated	Raymond James	Outperform	$5

Show Previous Ratings

Aug-06-26 07:30AM	Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +5.29%
Jul-17-26 10:42AM	Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 (GlobeNewswire)
Jun-30-26 09:00AM	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
May-28-26 07:30AM	Compass Therapeutics to Participate in Upcoming June Investor Events (GlobeNewswire) +6.17%
May-21-26 05:00PM	Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting (GlobeNewswire) +7.25%
07:30AM	Loading…
May-12-26 07:30AM	Compass Therapeutics to Participate in Upcoming May Investor Events (GlobeNewswire)
May-05-26 07:30AM	Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-28-26 10:30AM	BC-Most Active Stocks (Associated Press)
10:19AM	Micron initiated, Rambus downgraded: Wall Street's top analyst calls (The Fly)
07:21AM	Compass Therapeuticss stock crashes after OS miss in BTC trial (Clinical Trials Arena)
Apr-27-26 12:29PM	This Biotech Stock Is Down 61%. How a Cancer Trial Was Ruined by Its Own Design. (Barrons.com) -64.41%
10:30AM	BC-Most Active Stocks (Associated Press)
07:30AM	Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer (GlobeNewswire)
Apr-24-26 04:00PM	Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer (GlobeNewswire)
Mar-05-26 07:30AM	Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
09:40AM	Loading…
Feb-17-26 09:40AM	Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-29-26 09:40AM	Are Medical Stocks Lagging ResMed (RMD) This Year? (Zacks)
Jan-27-26 09:55AM	Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High? (Zacks)
Jan-19-26 05:00PM	Compass Therapeutics, Inc. (CMPX): A Bull Case Theory (Insider Monkey)
Jan-06-26 08:00AM	Compass Therapeutics Provides Corporate Update (GlobeNewswire)
Jan-05-26 04:30PM	Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Compass Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
Dec-21-25 07:31AM	Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment (Insider Monkey)
Dec-19-25 09:40AM	Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? (Zacks)
Dec-17-25 07:30AM	Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) -5.34%
Dec-12-25 09:55AM	Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet (Zacks)
Dec-08-25 12:00PM	Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy (Zacks)
Dec-03-25 09:15AM	Here Are Wednesdays Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendys and More (24/7 Wall St.)
Dec-01-25 01:04AM	Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement (Insider Monkey) -5.86%
Nov-26-25 09:55AM	Wall Street Analysts Believe Compass Therapeutics, Inc. (CMPX) Could Rally 154.09%: Here's is How to Trade (Zacks) +7.58%
08:00AM	Loading…
Nov-25-25 08:00AM	Compass Therapeutics to Participate in Upcoming December Investor Events (GlobeNewswire)
Nov-24-25 05:08AM	Zacks.com featured highlights include Orla Mining, FIGS and Compass Therapeutics (Zacks)
Nov-20-25 03:00PM	2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out! (Zacks)
Nov-18-25 06:17AM	Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development (Insider Monkey)
Nov-05-25 07:30AM	Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 09:00AM	Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-03-25 08:00AM	Compass Therapeutics to Participate in Upcoming November Investor Events (GlobeNewswire)
Oct-30-25 11:29PM	Piper Sandler Remains Bullish on Compass Therapeutics (CMPX) (Insider Monkey)
Sep-11-25 03:31AM	Guggenheim Sees Compass (CMPX) Potential Driven by Biliary Tract Cancer Pipeline (Insider Monkey)
Sep-02-25 12:57AM	Piper Sandler Reaffirms Optimism on Compass Therapeutics (CMPX) Amid Trial Update (Insider Monkey)
Aug-26-25 08:00AM	Compass Therapeutics to Participate in Upcoming September Investor Events (GlobeNewswire)
Aug-20-25 12:22AM	Compass Therapeutics (CMPX) Rated 'Outperform' amid Clinical Pipeline Development (Insider Monkey)
Aug-12-25 10:28PM	Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering (GlobeNewswire) -5.09%
04:01PM	Compass Therapeutics Announces Proposed Public Offering (GlobeNewswire)
03:03AM	Compass Therapeutics Inc (CMPX) Q2 2025 Earnings Call Highlights: Promising Clinical Advances ... (GuruFocus.com)
Aug-11-25 07:00AM	Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +23.70%
Aug-08-25 04:01PM	Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025 (GlobeNewswire)
Jul-25-25 12:09PM	Stifel Keeps Buy Rating on Compass Therapeutics (CMPX) (Insider Monkey)
Jul-22-25 11:03AM	Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline (Insider Monkey)
May-28-25 08:00AM	Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-08-25 08:00AM	Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-25 08:00AM	Compass Therapeutics to Participate in Upcoming May Investor Events (GlobeNewswire) -9.14%
Apr-28-25 08:00AM	Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-21-25 08:00AM	Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer (GlobeNewswire)
Apr-02-25 04:05PM	Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum (GlobeNewswire) -24.55% -5.03%
Apr-01-25 07:00AM	Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer (GlobeNewswire) +17.89%
Mar-31-25 04:05PM	Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer (GlobeNewswire)
Mar-27-25 10:20AM	Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-02-25 10:22AM	Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-27-25 08:00AM	Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-29-25 08:00AM	Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-08-25 08:00AM	Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate (GlobeNewswire) +30.07%
Dec-10-24 08:00AM	Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer (GlobeNewswire) +7.88%
Dec-02-24 08:00AM	Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 08:30AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire) -5.59%
Nov-12-24 08:00AM	Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire) -5.79%
Nov-08-24 10:05AM	Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Oct-04-24 10:31AM	Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-03-24 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-12-24 08:00AM	Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 08:00AM	Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference (GlobeNewswire) -6.52%
Aug-06-24 08:00AM	Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer (GlobeNewswire)
Jul-10-24 12:00PM	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why (Zacks) +9.94%
May-30-24 08:00AM	Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -7.48%
May-28-24 04:10PM	Compass Therapeutics Announces CEO Transition (GlobeNewswire)
May-23-24 05:05PM	Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 (GlobeNewswire)
May-14-24 08:00AM	Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-13-24 02:53PM	CMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-25-24 08:00AM	Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated (GlobeNewswire)
Apr-16-24 08:00AM	Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors (GlobeNewswire)
Apr-12-24 08:00AM	Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference (GlobeNewswire)
Apr-10-24 08:00AM	Compass Therapeutics to Participate in the Stifel Targeted Oncology Days (GlobeNewswire)
Apr-09-24 12:00PM	Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-21-24 10:54PM	CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +5.66%
09:00AM	Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-29-24 08:00AM	Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-28-24 08:00AM	Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial (GlobeNewswire)
Feb-08-24 12:00PM	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know (Zacks) +8.21%
Jan-05-24 08:00AM	Compass Therapeutics Provides Corporate Update (GlobeNewswire) +5.16%
Nov-09-23 08:17AM	Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) -6.40%
07:30AM	Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-30-23 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-03-23 08:00AM	Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-22-23 04:05PM	Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Jun-01-23 10:06AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
May-04-23 08:30AM	Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-23 08:30AM	Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Apr-19-23 08:30AM	Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days (GlobeNewswire) -5.00%

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Ph.D.Dr. Thomas J. Schuetz M.D.

M.B.A.Mr. Barry Shin J.D.

Senior VPMr. Jonathan E. Anderman J.D.

Senior VP & Chief Accounting OfficerMr. Neil L. Lerner CPA

Chief Scientific OfficerMr. Bing Gong Ph.D.

MBX MBX Biosciences Inc daily Stock Chart

Peers: KYMR BMRN CRNX INCY RYTM KRYS VKTX AXSM MDGL NBIX

| Held by: VTI IWM VXF IWO XPH IBB VTWO FESM SCHA IWC

Index	RUT
Market Cap	3.22B
Enterprise Value	2.81B
Income	-104.29M
Sales	0.00M
Book/sh	8.54
Cash/sh	8.69
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	63
IPO	Sep 13, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.83
P/C	7.69
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	18.08
Current Ratio	18.08
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.41
EPS next Y	-4.00
EPS next Q	-0.88
EPS this Y	-31.92%
EPS next Y	-27.54%
EPS next 5Y	-22.10%
EPS past 3/5Y	-44.91% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-4.40%
Sales Y/Y TTM	-
EPS Q/Q	-33.99%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-23.32% -

Insider Own	37.11%
Insider Trans	-0.29%
Inst Own	81.37%
Inst Trans	1.43%
ROA	-31.25%
ROE	-33.17%
ROIC	-25.30%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.46%
SMA50	12.70%
SMA200	71.61%
Trades

Shs Outstand	47.95M
Shs Float	30.29M
Short Float	17.13%
Short Ratio	6.78
Short Interest	5.19M
52W High	72.64 -7.93%
52W Low	9.63 594.47%
Volatility	4.40% 6.08%
ATR (14)	3.52
RSI (14)	56.55
Beta	0.07
Rel Volume	0.01
Avg Volume	765.25K
Volume	216

Perf Week	-2.01%
Perf Month	7.87%
Perf Quarter	109.97%
Perf Half Y	81.98%
Perf YTD	112.04%
Perf Year	366.69%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.08
Target Price	88.36
Prev Close	66.33
Price	66.88
Change %	0.82%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-21-26	Resumed	JP Morgan	Overweight	$88
Jan-28-26	Initiated	Barclays	Overweight	$66
Dec-04-25	Initiated	Goldman	Sell	$18
Nov-04-25	Initiated	TD Cowen	Buy
Oct-15-25	Initiated	Truist	Buy	$50
Aug-15-25	Resumed	Jefferies	Buy	$36
Aug-05-25	Initiated	Mizuho	Outperform	$38
Jul-16-25	Initiated	Oppenheimer	Outperform	$38
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Show Previous Ratings

Aug-14-26 07:05PM	UMH Properties and 4 More Stocks See Action From Activist Investors (Barrons.com)
Aug-06-26 08:00AM	MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-13-26 04:15PM	MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth (GlobeNewswire) -5.75%
Jun-12-26 08:52AM	MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX) (InvestorsHub)
07:00AM	MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism (GlobeNewswire)
05:27AM	Loading…
Jun-11-26 05:27AM	J&J looks to widen Imaavys use; $300M backs rare disease drug launch (BioPharma Dive) +20.20%
Jun-01-26 08:00AM	MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 (GlobeNewswire)
May-26-26 08:00AM	MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City (GlobeNewswire)
May-11-26 07:00AM	MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing (GlobeNewswire)
May-07-26 08:00AM	MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +8.06%
07:00AM	MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award (GlobeNewswire)
Apr-23-26 08:00AM	MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio (GlobeNewswire)
Apr-03-26 08:00AM	MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-12-26 08:00AM	MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-10-26 08:00AM	MBX Biosciences Appoints Karen Basbaum as Chief Business Officer (GlobeNewswire)
10:21AM	Loading…
Mar-09-26 10:21AM	CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism (GlobeNewswire) -8.54%
08:00AM	MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism (GlobeNewswire)
Feb-28-26 07:05PM	MBX Biosciences Calls 2026 Pivotal With Phase 3 Plans, Obesity Program, and $460M Cash Runway (MarketBeat)
Feb-23-26 08:00AM	MBX Biosciences to Participate in Upcoming March Investor Conferences (GlobeNewswire) +5.63%
Feb-20-26 06:53PM	TripAdvisor, Orthofix Medical, and More Stocks See Action From Activist Investors (Barrons.com) -6.63%
Feb-11-26 08:00AM	MBX Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.11%
Jan-22-26 08:00AM	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair (GlobeNewswire)
Jan-11-26 04:00PM	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 11:11PM	MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation (Insider Monkey)
08:00AM	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 (GlobeNewswire)
Dec-01-25 09:55AM	How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% (Zacks)
09:20AM	Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus (Zacks)
Nov-18-25 08:00AM	MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-14-25 09:55AM	Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Nov-06-25 08:00AM	MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) +9.71%
09:35AM	Loading…
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet (Zacks) +8.69%
Oct-20-25 08:00AM	MBX Biosciences to Participate in November Investor Conferences (GlobeNewswire) +7.64%
Oct-10-25 06:20PM	8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors (Barrons.com) -5.99%
Oct-09-25 09:55AM	Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Oct-08-25 07:00AM	Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates (Newsfile)
Sep-29-25 08:00AM	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Sep-24-25 09:15PM	MBX Biosciences Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.01% -13.78%
Sep-23-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet (Zacks) -5.20%
06:45AM	MBX to advance hypoparathyroidism drug to Phase III trial (Clinical Trials Arena)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
Sep-22-25 04:14PM	MBX Biosciences Announces Proposed Public Offering (GlobeNewswire) +100.00%
04:03PM	MBX Biosciences Stock Doubles On Promising New Thyroid Disease Treatment (Investor's Business Daily)
09:34AM	MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise (Investor's Business Daily)
08:28AM	MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study (Benzinga)
07:00AM	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension (GlobeNewswire)
Sep-19-25 04:18PM	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 (GlobeNewswire)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-04-25 08:00AM	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity (GlobeNewswire) -10.28%
Aug-20-25 12:13AM	MBX Biosciences Submits IND for Once-Monthly Obesity Drug (Insider Monkey)
Aug-07-25 08:00AM	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-05-25 09:37AM	Block downgraded, Wayfair upgraded: Wall Street's top analyst calls (The Fly)
Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Executive ChairpersonMr. Steven L. Hoerter

Executive OfficerMr. Peter Kent Hawryluk MBA

Chief Medical OfficerDr. Salomon Azoulay M.D.

Chief Financial OfficerMr. John W. Smither CPA

Senior Vice President of Investor Relations & Corporate CommunicationsMr. Pete De Spain

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hawryluk P. Kent	Former Officer	Aug 17 '26	Proposed Sale	68.29	3,745	255,737		Aug 17 03:41 PM
Azoulay Salomon	Chief Medical Officer	Aug 04 '26	Sale	65.77	370	24,335	14,399	Aug 05 04:57 PM
Hawryluk P. Kent	Officer	Aug 04 '26	Proposed Sale	65.77	936	61,563		Aug 04 04:44 PM
Azoulay Salomon	Officer	Aug 04 '26	Proposed Sale	65.77	370	24,336		Aug 04 04:42 PM
Bartram Richard	Former Officer	Jun 10 '26	Proposed Sale	30.55	9,167	280,010		Jun 10 12:41 PM
Bartram Richard	Former Officer	Jun 09 '26	Proposed Sale	29.66	10,833	321,273		Jun 09 04:38 PM
Bartram Richard	Former Officer	May 13 '26	Proposed Sale	36.95	15,000	554,296		May 13 04:17 PM
Azoulay Salomon	Chief Medical Officer	May 08 '26	Option Exercise	11.65	70,003	815,348	69,769	May 11 04:01 PM
Azoulay Salomon	Chief Medical Officer	May 08 '26	Sale	38.36	70,003	2,685,515	14,769	May 11 04:01 PM
Bartram Richard	Former Officer	May 11 '26	Proposed Sale	44.08	22,500	991,901		May 11 03:54 PM
Azoulay Salomon	Officer	May 08 '26	Proposed Sale	38.37	70,003	2,685,679		May 08 04:10 PM
Azoulay Salomon	Chief Medical Officer	May 06 '26	Sale	29.54	231	6,824	14,769	May 08 04:02 PM
Hawryluk P. Kent	President & CEO	May 06 '26	Sale	29.54	607	17,931	727,667	May 08 04:00 PM
Bartram Richard	Former Officer	May 08 '26	Proposed Sale	37.96	10,000	379,562		May 08 12:21 PM
Bartram Richard	Former Officer	May 07 '26	Proposed Sale	32.20	10,000	322,050		May 07 12:47 PM
Hawryluk P. Kent	Officer	May 06 '26	Proposed Sale	29.54	607	17,934		May 06 03:29 PM
Azoulay Salomon	Officer	May 06 '26	Proposed Sale	29.54	231	6,825		May 06 03:12 PM
Bartram Richard	Former Officer	May 01 '26	Proposed Sale	31.80	5,000	159,000		May 01 02:59 PM
Bartram Richard	Former Officer	Apr 22 '26	Proposed Sale	32.75	10,423	341,378		Apr 22 11:59 AM
Bartram Richard	Former Officer	Mar 25 '26	Proposed Sale	28.48	1,061	30,217		Mar 25 03:20 PM
Bartram Richard	Former Officer	Mar 16 '26	Proposed Sale	30.05	10,000	300,471		Mar 16 02:47 PM
Hawryluk P. Kent	President & CEO	Mar 13 '26	Buy	28.41	18,500	525,663	486,777	Mar 16 08:02 AM
Hawryluk P. Kent	President & CEO	Feb 26 '26	Option Exercise	16.00	28,768	460,288	728,274	Feb 27 04:07 PM
CORNELIUS JAMES M	Former Director	Jan 12 '26	Proposed Sale	35.74	30,864	1,102,991		Jan 12 03:41 PM
Hawryluk P. Kent	President & CEO	Oct 24 '25	Option Exercise	3.25	182,859	594,292	664,256	Oct 28 08:03 AM
Hawryluk P. Kent	President & CEO	Oct 20 '25	Buy	13.64	20,000	272,790	468,277	Oct 21 05:43 PM
Hoerter Steven L.	Director	Oct 17 '25	Buy	13.25	20,000	264,984	20,000	Oct 20 04:44 PM
Heron Patrick J	Director	Sep 26 '25	Buy	18.00	666,666	11,999,988	5,219,440	Sep 30 04:59 PM

BLSM

BlossomHill Therapeutics Inc

SCTX

Scribe Therapeutics Inc

CMPX

Compass Therapeutics Inc

MBX

MBX Biosciences Inc

Upgrade your Finviz experience